An act relating to health insurance coverage for biomarker testing

This bill requires most health insurance plans and Vermont Medicaid to cover biomarker testing when supported by specific evidence, such as FDA approvals, drug labels, or nationally recognized clinical guidelines. It directly affects patients needing these tests (e.g., for cancer diagnosis or treatment) and insurers/Medicaid, mandating coverage for tests analyzing genes, proteins, or other biological markers in blood or tissue. Key provisions include limiting disruptions in care (e.g., avoiding repeated biopsies) and defining biomarker testing broadly to include advanced genetic sequencing. The requirement takes effect January 1, 2026, for new plans, with Medicaid coverage pending CMS approval.